Follow-Up Study of Over Three Years of Patients with Uveitis after Cataract Phacoemulsification: Outcomes and Complications

Abbouda, Alessandro; Tortorella, Paolo; Restivo, Lucia; Santoro, E; Marco, Federica De; Cava, Maurizio La

doi:10.3109/08820538.2015.1009554

Cited by 19 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our investigation revealed that postoperative inflammation was higher in eyes in which iris retractors had been used. Consistent with our results, Abbouda et al suggested that the use of iris retractors induced postoperative inflammation [7]. Belovay et al also noted that excessive surgical manipulations and structural damage could trigger severe postoperative inflammation [21].…”

Section: Postoperative Inflammationsupporting

confidence: 92%

“…Despite intensive preoperative prophylaxis, severe postoperative inflammation that required additional treatment was observed in 6.6% of all eyes in our study. In the literature, severe postoperative inflammation was reported at rates of 3.7 to 10.9% in several studies [7,9,17,20]. Our investigation revealed that postoperative inflammation was higher in eyes in which iris retractors had been used.…”

Section: Postoperative Inflammationsupporting

confidence: 46%

“…Successful cataract management has been reported in several previous studies that have documented favorable anatomical and functional success rates with phacoemulsification and intraocular lens (IOL) implantation [4][5][6][7]. However, cataract surgery in eyes with uveitis poses a number of intraoperative and postoperative challenges, such as miotic pupil, synechiae, anterior segment bleeding, iris atrophy, excessive inflammation, high intraocular pressure (IOP), and cystoid macular edema (CME) [5,8,9].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Phacoemulsification in patients with uveitis: long-term outcomes

et al. 2020

View full text Add to dashboard Cite

Background: To assess the long-term outcomes of phacoemulsification and intraocular lens (IOL) implantation in eyes with uveitis. Methods: One hundred and five eyes of 81 patients, who underwent phacoemulsification and IOL implantation between January 2009 and July 2016, were included in this study. The demographic data, preoperative clinical findings, postoperative outcomes, and intraoperative and postoperative complications were recorded. All collected data and risk factors with regard to visual prognosis were analyzed with the help of the Statistical Package for the Social Sciences version 20.0 software program (IBM Corp., Armonk, NY, USA). Results: During follow-up (mean: 35.2 ± 22.2 months), corrected distance visual acuity (CDVA) improved in 87.7% of all eyes and reached a level of 0.3 LogMAR or greater in 61.3% of eyes. Postoperative complications included posterior capsule opacification (50.9%), posterior synechiae (21.7%), cystoid macular edema (16%), epiretinal membrane (13.2%), glaucoma (11.3%), increased intraocular pressure (8.5%), and severe inflammation (6.6%). Uveitis recurred in 55.7% of all eyes. The risk for the development of cystoid macular edema was found to be associated with recurrence in the early postoperative period. Low visual acuity risk was 11.1-fold higher with macular scarring (p = 0.001) and 14-fold higher with optic atrophy (p < 0.001), respectively. Conclusions: With appropriate management during the pre-and postoperative periods, phacoemulsification and IOL implantation surgery can be safe and effective in eyes with uveitis. However, great caution must be taken to prevent complications both before and after the surgery.

show abstract

Section: Postoperative Inflammationsupporting

confidence: 92%

Section: Postoperative Inflammationsupporting

confidence: 46%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Phacoemulsification in patients with uveitis: long-term outcomes

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Uveitis relapses in this study were defined as the presence of active inflammation which required an administration or increase in local or systemic immunosuppressive therapy. Uveitis relapse rates were calculated by counting the number of relapses per eye per year (EY) . The rate of using topical and systemic corticosteroids was measured by counting the number of months being on treatment per EY .…”

Section: Methodsmentioning

confidence: 99%

Long‐term effect of cataract phacoemulsification on the inflammation control and clinical outcome in uveitis patients^,

Sharief

Lightman

Baltinas

et al. 2018

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

show abstract

“…e most frequent ATT for patients with TBU is the use of four drugs (Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide) for 2 months followed by two drugs, Rifampicin and Isoniazid, for 4 months [13][14][15]. In addition, patients with TBU may develop ocular complications which require specific treatments, such as corticosteroids for cystoid macular edema (CME) or ocular surgery in patients with cataract [16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Clinical and Epidemiological Study on Tubercular Uveitis in a Tertiary Eye Care Centre in Italy

Cava

Sacchetti

Pirraglia

et al. 2020

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To describe frequency, clinical characteristics, and visual prognosis of tubercular uveitis (TBU) in a nonendemic country. Methods. We retrospectively reviewed 3743 charts of patients with endogenous uveitis visited from 2008 to 2018 at a tertiary referral centre in Rome, Italy. We included immunocompetent patients with diagnosis of TBU. Patients were divided in two groups: patients with history of uveitis without a previous diagnosis of TBU (group A) and patients at their first episode of TB uveitis (group B). Results. TBU was diagnosed in 28 (0.75%) out of 3743 patients. Twelve (42.9%) patients came from tuberculosis endemic areas. All patients received specific antitubercular treatment (ATT) and were evaluated for a mean follow-up of 3.2 ± 2.9 years. Group A showed a greater number of ocular complications when compared with group B. ATT was effective in reducing the frequency of recurrences of uveitis in patients of group B. Conclusion. Intraocular inflammation can be the first manifestation of tuberculosis. Our data highlight that early diagnosis and specific treatment of TBU may allow to decrease recurrences and to improve visual outcomes.

show abstract

Follow-Up Study of Over Three Years of Patients with Uveitis after Cataract Phacoemulsification: Outcomes and Complications

Abstract: The HR to develop ME was significantly related to chronic anterior uveitis. PCO and elevated IOP are most frequent in Fuchs uveitis. The postoperative visual acuity result was good among all the uveitis groups.

Cited by 19 publications

References 30 publications

Phacoemulsification in patients with uveitis: long-term outcomes

Phacoemulsification in patients with uveitis: long-term outcomes

Long‐term effect of cataract phacoemulsification on the inflammation control and clinical outcome in uveitis patients^,

Clinical and Epidemiological Study on Tubercular Uveitis in a Tertiary Eye Care Centre in Italy

Contact Info

Product

Resources

About

Follow-Up Study of Over Three Years of Patients with Uveitis after Cataract Phacoemulsification: Outcomes and Complications

Abstract: The HR to develop ME was significantly related to chronic anterior uveitis. PCO and elevated IOP are most frequent in Fuchs uveitis. The postoperative visual acuity result was good among all the uveitis groups.

Cited by 19 publications

References 30 publications

Phacoemulsification in patients with uveitis: long-term outcomes

Phacoemulsification in patients with uveitis: long-term outcomes

Long‐term effect of cataract phacoemulsification on the inflammation control and clinical outcome in uveitis patients,

Clinical and Epidemiological Study on Tubercular Uveitis in a Tertiary Eye Care Centre in Italy

Contact Info

Product

Resources

About

Long‐term effect of cataract phacoemulsification on the inflammation control and clinical outcome in uveitis patients^,